{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:55:55Z","timestamp":1791266155744,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Direct\u2010acting antivirals (DAAs) cure most chronic hepatitis C virus (HCV) infections, but their impact on liver functional reserve in patients with a history of hepatocellular carcinoma (HCC), particularly after non\u2010curative HCC treatment, remains unclear. We evaluated antiviral efficacy and liver functional reserve after DAA therapy according to HCC history and timing of DAA initiation. In this retrospective single\u2010center cohort, 716 patients initiated DAA therapy, and 690 with evaluable sustained virological response at 12\u2009weeks after treatment (SVR12) were analysed. Patients were classified as no HCC, curative\u2010treated HCC, or non\u2010curative\u2010treated HCC according to the most recent HCC treatment before DAA initiation. Liver functional reserve was assessed using the albumin\u2013bilirubin (ALBI) score, modified ALBI grade, and Child\u2013Pugh class. In the non\u2010curative\u2010treated HCC group, early (\u2264\u20093\u2009months) versus delayed (&gt;\u20093\u2009months) DAA initiation after the most recent HCC treatment was compared. Overall SVR12 was 96.1%, with similarly high rates across groups regardless of HCC history. The median ALBI score improved from \u22122.35 to \u22122.58 at SVR12 in the curative\u2010treated HCC group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) but remained unchanged in the non\u2010curative\u2010treated HCC group (\u22122.36 to \u22122.38). Among 64 patients with a history of HCC, 43 (67.2%) developed recurrence; in these patients, the ALBI score improved from \u22122.31 at DAA initiation to \u22122.57 at recurrence (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), and more than 90% remained Child\u2013Pugh class A. Early and delayed DAA initiation showed similarly high SVR12 rates and comparable liver functional reserve. DAAs achieved high SVR12 rates and maintained liver functional reserve in patients with HCV, including those with a history of HCC after non\u2010curative treatment.\n                  <\/jats:p>","DOI":"10.1111\/jvh.70242","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:26:57Z","timestamp":1791264417000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct\u2010Acting Antiviral Therapy in Patients With Hepatocellular Carcinoma Receiving Non\u2010Curative Treatment: High Sustained Virological Response Rates and Preservation of Liver Functional Reserve"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7480-7283","authenticated-orcid":false,"given":"Shunsuke","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nago","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihwa","family":"Om","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Terai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayato","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-7565","authenticated-orcid":false,"given":"Yuji","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0006-8948","authenticated-orcid":false,"given":"Takuya","family":"Genda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Juntendo University Shizuoka Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained Virologic Response to Direct\u2010Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Hepatocellular Carcinoma: A Systematic Review and Meta\u2010Analysis","volume":"71","author":"Ji F.","year":"2019","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy With Direct\u2010Acting Antivirals","volume":"66","author":"Prenner S. B.","year":"2017","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of Hepatitis C Antiviral Treatment in a USA Cohort of Veteran Patients With Hepatocellular Carcinoma","volume":"67","author":"Beste L. A.","year":"2017","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/cid\/ciz1160","article-title":"Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication","volume":"71","author":"Ogawa E.","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"Clinical Practice Guidelines Panel: Chair: EASL Governing Board representative: Panel members chairs. EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series","volume":"73","author":"European Association for the Study of the Liver","year":"2020","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","article-title":"Taiwan Consensus Statement on the Management of Hepatitis C: Part (II) Special Populations","volume":"119","author":"Yu M. L.","year":"2020","journal-title":"Journal of the Formosan Medical Association"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma","volume":"78","author":"Singal A. G.","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn R. S.","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma","volume":"82","author":"European Association for the Study of the Liver","year":"2025","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence\u2010Based Approach\u2010The ALBI Grade","volume":"33","author":"Johnson P. J.","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000479984","article-title":"Validation and Potential of Albumin\u2010Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function","volume":"6","author":"Hiraoka A.","year":"2017","journal-title":"Liver Cancer"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular Carcinoma Risk Following Direct\u2010Acting Antiviral HCV Therapy: A Systematic Review, Meta\u2010Analyses, and Meta\u2010Regression","volume":"67","author":"Waziry R.","year":"2017","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct\u2010Acting Antivirals After Successful Treatment of Early Hepatocellular Carcinoma Improve Survival in HCV\u2010Cirrhotic Patients","volume":"71","author":"Cabibbo G.","year":"2019","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233212","article-title":"Impact of Direct\u2010Acting Antiviral Therapy for Hepatitis C\u2010Related Hepatocellular Carcinoma","volume":"15","author":"Lin W. C.","year":"2020","journal-title":"PLoS One"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"17081","DOI":"10.1038\/s41598-019-53051-2","article-title":"Impact of Direct Acting Antivirals on Survival in Patients With Chronic Hepatitis C and Hepatocellular Carcinoma","volume":"9","author":"Kamp W. M.","year":"2019","journal-title":"Scientific Reports"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic Benefits of HCV Cure","volume":"73","author":"Calvaruso V.","year":"2020","journal-title":"Journal of Hepatology"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/hep4.1412","article-title":"Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV\u2010TARGET Analysis","volume":"3","author":"Radhakrishnan K.","year":"2019","journal-title":"Hepatology Communication"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026703","article-title":"Equal Treatment Efficacy of Direct\u2010Acting Antivirals in Patients With Chronic Hepatitis C and Hepatocellular Carcinoma? A Prospective Cohort Study","volume":"9","author":"Huang C. F.","year":"2019","journal-title":"BMJ Open"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3350\/cmh.2024.1015","article-title":"Direct\u2010Acting Antiviral Therapy for Patients With Hepatitis C Virus\u2010Related Hepatocellular Carcinoma: A Nationwide Cohort Study","volume":"31","author":"Lee S. W.","year":"2025","journal-title":"Clinical and Molecular Hepatology"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.70242","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:27:02Z","timestamp":1791264422000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/jvh.70242"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70242","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"2026-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70242"}}